# Nadine Tung

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nadine-tung/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,146 |
| Field | BRCA gene mutations in cancer |
| h-index | 84 |
| i10-index | 225 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5051532432 |
| ORCID iD | https://orcid.org/0000-0003-1422-3734 |
| Works | 483 |

## Researcher papers

- [Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for/)
- [Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-2/)
- [Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1</i> / <i>2</i> (CIMBA)](https://scholariq.org/papers/pathology-of-breast-and-ovarian-cancers-among-i-brca1-i-and-i-brca2-i-mutation/)
- [Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer](https://scholariq.org/papers/association-of-type-and-location-of-i-brca1-i-and-i-brca2-i-mutations-with-risk/)
- [Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment](https://scholariq.org/papers/clinical-actionability-of-multigene-panel-testing-for-hereditary-breast-and/)
- [Identification of six new susceptibility loci for invasive epithelial ovarian cancer](https://scholariq.org/papers/identification-of-six-new-susceptibility-loci-for-invasive-epithelial-ovarian/)

## Researcher topics

- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.